Advancing pharmaceuticals and patient safety in Saudi Arabia: A 2030 vision initiative
Pitts, Tariq M Alhawassi, Hatem A Abuelizz, Mansour Almetwazi, Mansour A Mahmoud, Ahmed Alghamdi, Yazed S Alruthia, Nasser BinDhim, Khalid A Alburikan, Yousif A Asiri, Peter J . 2017
Low-quality medicines deliver sub-optimal clinical outcomes and waste precious health resources. It is important to ensure that public funds are spent on healthcare technologies that meet national regulatory bodies such as the Saudi Food and Drug Authority (SFDA), quality standards for safety, efficacy, and quality. Medicines quality is a complicated combination of pre-market regulatory specifications, appropriate sourcing of ingredients (active pharmaceutical ingredient (API), excipients, etc.), manufacturing processes, healthcare ecosystem communications, and regular and robust pharmacovigilancepractices. A recent conference in Riyadh, sponsored by King Saud University, sought to discuss these issues and develop specific policy recommendations for the Saudi 2030 Vision plan. This and other efforts will require more and more creative educational programs for physicians, pharmacists, hospitals, and patients, and, most importantly evolving regulations on quality standards and oversight by Saudi health authorities.
The pseudoglycosyltransferase (PsGT) VldE is a glycosyltransferase-like protein that is similar to trehalose 6-phosphate synthase (OtsA). However, in contrast to OtsA, which catalyzes condensation…
The title compound, C18H20N4O2S2, is a new 1,3,4-oxadiazole and a key pharmacophore of several biologically active agents. It is composed of a methyl(thiophen-2-yl)-1,3,4-oxadiazole-2(3H…
C31H36F2N6S, monoclinic, P21/c (no. 14), a = 14.7561(8) Å, b = 24.6766(13) Å, c = 7.7811(4) Å, β = 95.888(2)°, V = 2818.4(3) Å3, …